4.2.2 Application of PD-1 and PD-L1 Inhibitors in Cancer
On December 18, 2015, pembrolizumab received an expanded first-line indication to include previouslyuntreated advanced melanoma regardless of BRAF mutation status following the results of the KEYNOTE-006 trial (Table 4.2).(https://www.daowen.com)
